PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|July 1, 2013
Bruker Offers LC Triple Quadrupole Mass Spectrometers
Author(s)Pharmaceutical Technology Editors
Bruker Chemical and Applied Markets offers three LC-triple quadrupole (LC-TQ) mass spectrometers, the EVOQ Qube, the EVOQ Elite, and the EVOQ Elite ER.
Bruker Chemical and Applied Markets (CAM) offers three LC-triple quadrupole (LC-TQ) mass spectrometers, the EVOQ Qube, the EVOQ Elite, and the EVOQ Elite ER.
All systems incorporate Bruker’s Advance Ultra-High Pressure Liquid Chromatography (UHPLC) systems. The Advance HPLC, UHPLC, and the UHPLC-OLE products offer ultra-low dead-volume, which enables excellent reproducibility at analytical flow-rates, an integrated column-oven, and bench-space savings,
Innovations include the first Vacuum-Insulated Probe (VIP) heated electrospray technology, which preserves and ionizes thermally fragile molecules; an Active Exhaust atmospheric pressure ionization source with a robust orifice vacuum interface, which enhances quantitative robustness for difficult samples; a proprietary Interlaced Quadrupole Dual Funnel (IQ-DF), which maximizes sensitivity; and, PACER software, which enables ‘exception based data-review’, a revolutionary feature that significantly reduces the error rate for quantitative analysis.
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.